Pacira BioSciences Inc [NASDAQ: PCRX] closed the trading session at $22.74.
The stocks have a year to date performance of -32.60 percent and weekly performance of -19.87 percent. The stock has been moved at -32.60 percent over the last six months. The stock has performed -25.02 percent around the most recent 30 days and changed -20.24 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 760.79K shares, PCRX reached to a volume of 9124525 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pacira BioSciences Inc [PCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PCRX shares is $43.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PCRX stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Pacira BioSciences Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 07, 2024. While these analysts kept the previous recommendation, Raymond James raised their target price to Outperform. The new note on the price target was released on December 20, 2023, representing the official price target for Pacira BioSciences Inc stock. Previously, the target price had yet another raise to $50, while TD Cowen analysts kept a Outperform rating on PCRX stock. On January 31, 2023, analysts decreased their price target for PCRX shares from 88 to 60.
The Average True Range (ATR) for Pacira BioSciences Inc is set at 1.55, with the Price to Sales ratio for PCRX stock in the period of the last 12 months amounting to 1.55. The Price to Book ratio for the last quarter was 1.19, with the Price to Cash per share for the same quarter was set at 7.00. Price to Free Cash Flow for PCRX in the course of the last twelve months was 6.11 with Quick ratio for the last quarter at 4.78.
PCRX stock trade performance evaluation
Pacira BioSciences Inc [PCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.87. With this latest performance, PCRX shares dropped by -25.02% in over the last four-week period, additionally sinking by -32.60% over the last 6 months – not to mention a drop of -43.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PCRX stock in for the last two-week period is set at 25.66, with the RSI for the last a single of trading hit 19.83, and the three-weeks RSI is set at 30.44 for Pacira BioSciences Inc [PCRX]. The present Moving Average for the last 50 days of trading for this stock 28.59, while it was recorded at 27.07 for the last single week of trading, and 29.61 for the last 200 days.
Pacira BioSciences Inc [PCRX]: An insightful look at the core fundamentals
Pacira BioSciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.78 and a Current Ratio set at 5.81.
Earnings per share (EPS) analysis for Pacira BioSciences Inc [PCRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacira BioSciences Inc go to 9.70%.
Pacira BioSciences Inc [PCRX]: Institutional Ownership
The top three institutional holders of PCRX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in PCRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in PCRX stock with ownership which is approximately 5.1238%.
